Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

GSK plc has an exclusive global license option to co-develop and commercialize XMT-2056. At the Society for Immunotherapy of ...

Curevac N.V. ( (CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. CureVac ...

Google.org awards USD 1 million to Karya, an Indian non-profit, to empower low-income communities with AI skills, creating ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

"Since joining Apriori last year, I have been deeply impressed with the capabilities and advancement of our Octavia platform and the progress we have made toward bringing new vaccines to patients ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

A St. Louis-based clinical-stage biotechnology company developing cancer-fighting drugs has hired a new medical chief ...

Exclusive: New Details Emerge on QXO’s Go-to-Market Plans (August) “Artificial intelligence will permeate everything we do at ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...